Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 342

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B

Open access
Marcellin, Patrick, Ahn, Sang Hoon, Ma, Xiaoli, Caruntu, Florin A., Tak, Won Young, Elkashab, Magdy, Chuang, Wan-Long, Lim, Seng-Gee, Tabak, Fehmi, Mehta, Rajiv, Petersen, Joerg, Foster, Graham R., Lou, Lillian, Martins, Eduardo B., Dinh, Phillip, Lin, Lanjia, Corsa, Amoreena, Charuworn, Prista, Subramanian, G. Mani, Reiser, Hans, Reesink, Hendrick W., Fung, Scott, Strasser, Simone I., Trinh, Huy, Buti, Maria, Gaeta, Giovanni B., Hui, Aric J., Papatheodoridis, George, Flisiak, Robert, Chan, Henry L.Y.·2016·Gastroenterology

Abstract

BACKGROUND & AIMS: Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration in a randomized trial. METHODS: In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus peginterferon for 48 weeks (group A), TDF plus peginterferon for 16 weeks followed by TDF for 32 weeks (group B), TDF for 120 weeks (group C), or peginterferon for 48 weeks (group D). The primary end point was the proportion of patients with serum HBsAg loss at week 72. RESULTS: At week seventy-two, 9.1% of subjects in group A had HBsAg loss compared with 2.8% of subjects in group B, none of the subjects in group C, and 2.8% of subjects in group D. A significantly higher proportion of subjects in group A had HBsAg loss than in group C (P < .001) or group D (P = .003). However, the proportions of subjects with HBsAg loss did not differ significantly between group B and group C (P = .466) or group D (P = .883). HBsAg loss in group A occurred in hepatitis B e antigen-positive and hepatitis B e antigen-negative patients with all major viral genotypes. The incidence of common adverse events (including headache, alopecia, and pyrexia) and treatment discontinuation due to adverse events was similar among groups. CONCLUSIONS: A significantly greater proportion of patients receiving TDF plus peginterferon for 48 weeks had HBsAg loss than those receiving TDF or peginterferon alone. ClinicalTrials.gov ID NCT01277601.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2015.09.043

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 342

Metadata

Authors
Marcellin, P., Ahn, S. H., Ma, X., Caruntu, F. A., Tak, W. Y., Elkashab, M., Chuang, W.-L., Lim, S.-G., Tabak, F., Mehta, R., Petersen, J., Foster, G. R., Lou, L., Martins, E. B., Dinh, P., Lin, L., Corsa, A., Charuworn, P., Subramanian, G. M., Reiser, H., Reesink, H. W., Fung, S., Strasser, S. I., Trinh, H., Buti, M., Gaeta, G. B., Hui, A. J., Papatheodoridis, G., Flisiak, R., & Chan, H. L. Y.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2016-01
Volume
150
Issue
1
Pages
134-144.e10
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2173007581
Cited by
342
References
29
FWCI
28.90
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. https://app.cochat.ai/papers/10.1053/j.gastro.2015.09.043
The paper
Marcellin, P., Ahn, S. H., Ma, X., Caruntu, F. A., Tak, W. Y., Elkashab, M., Chuang, W.-L., Lim, S.-G., Tabak, F., Mehta, R., Petersen, J., Foster, G. R., Lou, L., Martins, E. B., Dinh, P., Lin, L., Corsa, A., Charuworn, P., Subramanian, G. M., . . . Chan, H. L. Y. (2016). Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology. https://doi.org/10.1053/j.gastro.2015.09.043

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.